Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,061 to 3,080 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: serious adverse events | 113 of 1,208 126 of 1,200 | -1.1 points -3.5 to 1.2 | 2,408 | NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project |
| CHARM2 Intervention vs Control: deaths from any cause | 3 of 1,200 3 of 1,202 | 0.0 points -0.5 to 0.5 | 2,402 | NCT03514914 Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy |
| QIVc vs Comparator QIV: deaths from any cause | 2 of 1,597 0 of 805 | 0.1 points -0.4 to 0.5 | 2,402 | NCT04074928 Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects |
| QIVc vs Comparator QIV: serious adverse events | 15 of 1,597 7 of 805 | 0.1 points -0.9 to 0.8 | 2,402 | NCT04074928 Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 186 of 1,186 188 of 1,212 | 0.2 points -2.7 to 3.1 | 2,398 | NCT02173379 Absorb IV Randomized Controlled Trial |
| V114 vs Prevnar 13™: serious adverse events | 192 of 1,965 45 of 433 | -0.6 points -4.1 to 2.3 | 2,398 | NCT03692871 A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) |
| Alert vs Usual Care: Death | 71 of 1,201 61 of 1,192 | 0.8 points -1.0 to 2.6 | 2,393 | NCT01862419 An Electronic Alert System for In-Hospital Acute Kidney Injury |
| Alert vs Usual Care: Dialysis Within 7 Days | 87 of 1,201 70 of 1,192 | 1.4 points -0.6 to 3.4 | 2,393 | NCT01862419 An Electronic Alert System for In-Hospital Acute Kidney Injury |
| Canadian C-Spine Rule vs Control Phase (Usual Care): Proportion of Patients Feeling Uncomfortable | 654 of 1,108 883 of 1,285 | -9.7 points -13.5 to -5.8 | 2,393 | NCT02786966 A Pragmatic Evaluation of the Canadian C-Spine Rule by Paramedics |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 91 of 1,189 81 of 1,200 | 0.9 points -1.2 to 3.0 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 171 of 1,189 155 of 1,200 | 1.5 points -1.3 to 4.2 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 114 of 1,189 82 of 1,200 | 2.8 points 0.6 to 5.0 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 89 of 1,189 80 of 1,200 | 0.8 points -1.2 to 2.9 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 262 of 1,189 240 of 1,200 | 2.0 points -1.2 to 5.3 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 134 of 1,189 106 of 1,200 | 2.4 points 0.0 to 4.9 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 209 of 1,189 188 of 1,200 | 1.9 points -1.1 to 4.9 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 111 of 1,189 82 of 1,200 | 2.5 points 0.3 to 4.7 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 77 of 1,189 72 of 1,200 | 0.5 points -1.5 to 2.4 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 233 of 1,189 207 of 1,200 | 2.3 points -0.8 to 5.5 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 310 of 1,189 284 of 1,200 | 2.4 points -1.1 to 5.9 | 2,389 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=154"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=154
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02299414-sae",
"title": "Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: serious adverse events",
"summary": "113 of 1208 against 126 of 1200; risk difference -1.1 points, 95% interval -3.5 to 1.2; NCT02299414, Chronic Hypertension and Pregnancy (CHAP) Project",
"record": "/library/comparisons/NCT02299414-sae",
"nct_id": "NCT02299414",
"kind": "serious-adverse-events",
"participants": 2408,
"risk_difference": {
"value": -0.011456953642384096,
"lower": -0.035468434674659,
"upper": 0.012496492166721874
},
"group_1": "113 of 1,208",
"group_2": "126 of 1,200",
"difference": "-1.1 points",
"interval": "-3.5 to 1.2",
"trial_title": "Chronic Hypertension and Pregnancy (CHAP) Project"
},
{
"id": "NCT03514914-deaths",
"title": "CHARM2 Intervention vs Control: deaths from any cause",
"summary": "3 of 1200 against 3 of 1202; risk difference 0.0 points, 95% interval -0.5 to 0.5; NCT03514914, Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy",
"record": "/library/comparisons/NCT03514914-deaths",
"nct_id": "NCT03514914",
"kind": "deaths",
"participants": 2402,
"risk_difference": {
"value": 0.00000415973377703837,
"lower": -0.005086916959551913,
"upper": 0.005101902963710504
},
"group_1": "3 of 1,200",
"group_2": "3 of 1,202",
"difference": "0.0 points",
"interval": "-0.5 to 0.5",
"trial_title": "Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=155",
"request_id": "t1YCH2QmonAsglYS"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant